LTFS
IMUC

Ladenburg Thalmann Financial Services’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-45
Closed – – 5217
2017
Q2 		$0 Hold
45
– – ﹤0.01% 5162
2017
Q1 		$0 Sell
45
-25
-36% -$65 ﹤0.01% 5167
2016
Q4 		$0 Hold
70
– – ﹤0.01% 5137
2016
Q3 		$0 Hold
70
– – ﹤0.01% 5089
2016
Q2 		$0 Buy
70
+25
+56% +$257 ﹤0.01% 5071
2016
Q1 		$1K Hold
45
– – ﹤0.01% 4657
2015
Q4 		$1K Hold
45
– – ﹤0.01% 4648
2015
Q3 		$1K Hold
45
– – ﹤0.01% 4573
2015
Q2 		$1K Hold
45
– – ﹤0.01% 4625
2015
Q1 		$1K Hold
45
– – ﹤0.01% 4550
2014
Q4 		$1K Buy
45
+20
+80% +$576 ﹤0.01% 4328
2014
Q3 		$1K Hold
25
– – ﹤0.01% 3900
2014
Q2 		$1K Hold
25
– – ﹤0.01% 3869
2014
Q1 		$1K Buy
+25
New +$1.22K ﹤0.01% 3729

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Ladenburg Thalmann Financial Services's IMUC Position: Q3 2017 in Review

Ladenburg Thalmann Financial Services sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2017, closing a stake of 45 shares.

Ladenburg Thalmann Financial Services first reported a position in IMUC in Q1 2014 and held it in 14 quarters. The position peaked at $1K in Q1 2016. 18 funds tracked by Wall St. Rank hold IMUC as of Q3 2017.

  • Ladenburg Thalmann Financial Services reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2017 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 45 ImmunoCellular Therapeutics, Ltd. shares in Q3 2017.
  • Ladenburg Thalmann Financial Services first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2014 and held it in 14 quarters.
  • Ladenburg Thalmann Financial Services's ImmunoCellular Therapeutics, Ltd. position peaked at $1K in Q1 2016.
  • 18 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2017.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2017, filed 15 Nov 2017.